Granisetron (Kytril) plus dexamethasone for antiemetic control in bone marrow transplant patients receiving highly emetogenic chemotherapy with or without total body irradiation

Bone Marrow Transplantation

Volumn 25, Issue 12, 2000, Pages 1279-1283

  Abbott, B ^a,b   Ippoliti, C ^a   Hecth, D ^a   Bruton, J ^a   Whaley, B ^a   Champlin, R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Ortho Biotech Oncology   (United States)

Author keywords

Antiemetic; Bone marrow transplant; Chemotherapy; Dexamethasone; Granisetron; Total body irradiation

Indexed keywords

ANTIEMETIC AGENT; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; GRANISETRON; PROCHLORPERAZINE; THIOTEPA;

ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; FEMALE; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; VOMITING; WHOLE BODY RADIATION;

EID: 0033932919     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702424     Document Type: Article

References (16)

1. Coates A, Abraham S, Haye SB et al. On the receiving end - patient perception of the side effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983; 19: 203-208.
2. Clavel M, Soukop M, Greenstreet YL. Improved control of emesis and quality of life with ondansetron in breast cancer. Oncology 1993; 50: 180-185.
3. Perez EA, Gandara DR. Advances in the control of chemotherapy-induced emesis. Ann Oncol 1992; 3: S47-S50.
4. Mitchell EP, Schein PS. Gastrointestinal toxicity of chemotherapy agents. In: Perry MC (ed). The Chemotherapy Sourcebook. Williams & Wilkins: Baltimore, 1992, pp 620-634.
5. Dodds LJ. The control of cancer chemotherapy-induced nausea and vomiting. J Clin Hosp Pharm 1995; 10: 143-166.
6. Ettinger CS. Preventing chemotherapy-induced nausea and vomiting: an update and a review of emesis. Semin Oncol 1995; 22 (Suppl. 10): 6-18.
7. Plosker GL, Goa KL. Granisetron: a review of its pharmacological properties and therapeutic use as an antiemetic. Drugs 1991; 42: 805-824.
8. Okamoto S, Takahashi S, Tanosaki R et al. Granisetron in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study. Bone Marrow Transplant 1996; 17: 679-683.
9. 3 receptor antagonist, for the prevention of radiation induced emesis during total body irradiation. Bone Marrow Transplant 1991; 7: 439-441.
10. Prentice HG, Cunningham S, Ghandhi L et al. Granisetron in the prevention of irradiation-induced emesis. Bone Marrow Transplant 1995; 15: 445-487.
11. Roberts JT, Priestman TJ. A review of ondansetron in the management of radiotherapy-induced emesis. Oncology 1993; 50: 173-179.
12. Kamamabrou D. Intravenous granisetron-establishing the optimal dose. Eur J Cancer 1992; 28A (Suppl. 1): S6-S11.
13. Heron JF, Goedhals L, Jordaan JP et al. Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. Ann Oncol 1994; 5: 579-584.
14. Abbott B, Ippoliti C, Bruton J et al. Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation. Bone Marrow Transplant 1999; 23: 265-269.
15. 3 antagonist. Bone Marrow Transplant 1991; 7: 431-433.
16. Barbounis V, Koumakis G, Vassilomanolakis M et al. A phase II study of ondansetron as antiemetic prophylaxis in patients receiving high-dose polychemotherapy and stem cell transplantation. Support Care Cancer 1995; 3: 301-306.